Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment.

Pharmaceuticals (Basel) · 2023 · PMC10055947 · PMID 36986473

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

For the differences between two groups, * p < 0.05 and ** p < 0.01 were considered significant, and *** p < 0.001 and **** p < 0.0001 were considered highly significant. 5.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.